cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
8 own
Current Price
$4.64
$-0.42
(-8.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
218.53M
52-Week High
52-Week High
12.69000
52-Week Low
52-Week Low
1.53500
Average Volume
Average Volume
0.63M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization218.53M
icon52-Week High12.69000
icon52-Week Low1.53500
iconAverage Volume0.63M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Business Wire
11 months ago
2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023. 2seventy bio will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update...
Globe Newswire
1 year ago
Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum continues with a $3 million milestone payment from 2seventy bioStrengthened leadership with key hires in Corporate ...
Business Wire
1 year ago
2seventy bio, Inc. (Nasdaq: TSVT) today announced the appointment of Wei Lin, M.D. to the companys Board of Directors, effective immediately. We are thrilled to welcome Dr. Wei Lin to 2seventys Board during an exciting time in our Companys growth, said Nick Leschly, chief kairos officer. Weis...
Business Wire
1 year ago
2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the 43rd Annual TD Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, MA on March 7, 2023 at 10:30am ET. A live webcast will be available via the Investors and...
Business Wire
1 year ago
2seventy bio, Inc. (2seventy bio) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$4.64
$-0.42
(-8.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00